Who are Methylphenidate, aripiprazole, and combination's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methylphenidate-aripiprazole-and-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Methylphenidate, aripiprazole, and combination — Competitive Intelligence Brief

Methylphenidate, aripiprazole, and combination (Methylphenidate, aripiprazole, and combination) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Stimulant and atypical antipsychotic combination. Area: Psychiatry / Neurology.

marketed Stimulant and atypical antipsychotic combination Dopamine transporter (DAT), norepinephrine transporter (NET), dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Methylphenidate, aripiprazole, and combination (Methylphenidate, aripiprazole, and combination) — Tri-Service General Hospital. This combination uses methylphenidate to increase dopamine and norepinephrine activity, while aripiprazole acts as a dopamine partial agonist to modulate psychotic symptoms and mood.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Methylphenidate, aripiprazole, and combination TARGET	Methylphenidate, aripiprazole, and combination	Tri-Service General Hospital	marketed	Stimulant and atypical antipsychotic combination	Dopamine transporter (DAT), norepinephrine transporter (NET), dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Stimulant and atypical antipsychotic combination class)

Tri-Service General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methylphenidate, aripiprazole, and combination — Competitive Intelligence Brief. https://druglandscape.com/ci/methylphenidate-aripiprazole-and-combination. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab